|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
VETOES
|
|
|
|
|
S.B. 909
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Dear Mr. President:
In accordance with Article II, Section 17 of the Maryland Constitution, today I have
vetoed Senate Bill 909 - Task Force to Study the Impact of Autoimmune Disease in
Maryland.
This bill establishes the Task Force to Study the Impact of Autoimmune Disease in
Maryland. Senate Bill 909 provides for the membership and duties of the Task Force
and requires the Task Force to submit a report to the Governor and the General
Assembly.
House Bill 1494, which was passed by the General Assembly and signed by me,
accomplishes the same purpose. Therefore, it is not necessary for me to sign Senate
Bill 909.
Very truly yours,
Robert L. Ehrlich, Jr.
Governor
Senate Bill No. 909
AN ACT concerning
Task Force to Study the Impact of Autoimmune Disease in Maryland
FOR the purpose of establishing the Task Force to Study the Impact of Autoimmune
Disease in Maryland; providing for the membership, chair, and staff for the Task
Force; providing that a member of the Task Force may receive certain
reimbursement as provided in the State budget; providing for the duties of the
Task Force; requiring the Task Force to submit certain reports to the Governor
and the General Assembly on or before certain dates; providing for the
termination of this Act; and generally relating to the Task Force to Study the
Impact of Autoimmune Disease in Maryland.
SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF
MARYLAND, That:
(a) There is a Task Force to Study the Impact of Autoimmune Disease in
Maryland.
(b) The Task Force consists of the following members:
(1) one member of the Senate of Maryland, appointed by the President of
the Senate;
(2) one member of the House of Delegates, appointed by the Speaker of
the House;
(3) a representative of the Department of Health and Mental Hygiene,
appointed by the Secretary of Health and Mental Hygiene;
(4) a representative of the Maryland Insurance Administration, selected
by the Administration;
- 3948 -
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
